全文获取类型
收费全文 | 12027篇 |
免费 | 687篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 123篇 |
儿科学 | 234篇 |
妇产科学 | 279篇 |
基础医学 | 1599篇 |
口腔科学 | 229篇 |
临床医学 | 1234篇 |
内科学 | 2713篇 |
皮肤病学 | 132篇 |
神经病学 | 1229篇 |
特种医学 | 393篇 |
外科学 | 1730篇 |
综合类 | 140篇 |
一般理论 | 13篇 |
预防医学 | 826篇 |
眼科学 | 208篇 |
药学 | 915篇 |
中国医学 | 9篇 |
肿瘤学 | 764篇 |
出版年
2023年 | 60篇 |
2022年 | 36篇 |
2021年 | 197篇 |
2020年 | 159篇 |
2019年 | 181篇 |
2018年 | 204篇 |
2017年 | 174篇 |
2016年 | 156篇 |
2015年 | 255篇 |
2014年 | 332篇 |
2013年 | 530篇 |
2012年 | 806篇 |
2011年 | 828篇 |
2010年 | 434篇 |
2009年 | 385篇 |
2008年 | 703篇 |
2007年 | 771篇 |
2006年 | 765篇 |
2005年 | 743篇 |
2004年 | 716篇 |
2003年 | 662篇 |
2002年 | 671篇 |
2001年 | 239篇 |
2000年 | 209篇 |
1999年 | 240篇 |
1998年 | 147篇 |
1997年 | 142篇 |
1996年 | 107篇 |
1995年 | 111篇 |
1994年 | 84篇 |
1993年 | 81篇 |
1992年 | 123篇 |
1991年 | 117篇 |
1990年 | 100篇 |
1989年 | 100篇 |
1988年 | 82篇 |
1987年 | 77篇 |
1986年 | 87篇 |
1985年 | 76篇 |
1984年 | 65篇 |
1983年 | 48篇 |
1982年 | 75篇 |
1981年 | 44篇 |
1979年 | 46篇 |
1978年 | 46篇 |
1977年 | 52篇 |
1976年 | 46篇 |
1975年 | 61篇 |
1974年 | 37篇 |
1973年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Raphael Mohr Robert Schierwagen Carolynne Schwarze-Zander Christoph Boesecke Jan-Christian Wasmuth Jonel Trebicka Jürgen Kurt Rockstroh 《Medicine》2015,94(50)
Liver-related death in human immunodeficiency virus (HIV)-infected individuals is about 10 times higher compared with the general population, and the prevalence of significant liver fibrosis in those with HIV approaches 15%. The present study aimed to assess risk factors for development of hepatic fibrosis in HIV patients receiving a modern combination anti-retroviral therapy (cART).This cross-sectional prospective study included 432 HIV patients, of which 68 (16%) patients were anti-hepatitis C virus (HCV) positive and 23 (5%) were HBsAg positive.Health trajectory including clinical characteristics and liver fibrosis stage assessed by transient elastography were collected at inclusion. Liver stiffness values >7.1 kPa were considered as significant fibrosis, while values >12.5 kPa were defined as severe fibrosis. Logistic regression and Cox regression uni- and multivariate analyses were performed to identify independent factors associated with liver fibrosis.Significant liver fibrosis was detected in 10% of HIV mono-infected, in 37% of HCV co-infected patients, and in 18% of hepatitis B virus co-infected patients. The presence of diabetes mellitus (odds ratio [OR] = 4.6) and FIB4 score (OR = 2.4) were independently associated with presence of significant fibrosis in the whole cohort. Similarly, diabetes mellitus (OR = 5.4), adiposity (OR = 4.6), and the FIB4 score (OR = 3.3) were independently associated with significant fibrosis in HIV mono-infected patients. Importantly, cumulative cART duration protected, whereas persistent HIV viral replication promoted the development of significant liver fibrosis along the duration of HIV infection.Our findings strongly indicate that besides known risk factors like metabolic disorders, HIV may also have a direct effect on fibrogenesis. Successful cART leading to complete suppression of HIV replication might protect from development of liver fibrosis. 相似文献
3.
Jessica Roberts MBBS Jason Powell MBBS MClinRes PhD MRCS Jacob Begbie MBBS MRes Gerard Siou MBBS MD FRCS Claire McLarnon MBBS MSc FRCS Andrew Welch MBBS FRCS Michael McKean MBChB MD FRCPCH Mathew Thomas MBChB MRCPCH PhD Anne-Marie Ebdon MBBS MRCPCH FRACP Samantha Moss MBBS MRCPCH MD Rachel S. Agbeko MSc MD PhD FRCPCH FFICM Jonathan H. Smith MBChB MRCP FRCA Malcolm Brodlie MB ChB PhD MRCPCH Christopher O'Brien MBBS FRCPCH Steven Powell MBBS MSc FRCS 《The Laryngoscope》2020,130(5):E375-E380
4.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.5.
Steven V Koenen Anjoke J M Huisjes Jules Dings Yolanda van der Graaf Gerard H A Visser Hein W Bruinse 《The journal of maternal-fetal & neonatal medicine》2006,19(2):93-99
OBJECTIVE: To determine if there is a diurnal pattern in the clinical symptoms of HELLP (Hemolysis, Elevated Liver enzymes, Low Platelets) syndrome. STUDY DESIGN: A retrospective study was performed in 134 pregnancies complicated by HELLP syndrome. The medical records were reviewed to describe each HELLP episode. Time of day was divided into three periods, day, evening, and night. The following parameters were categorized according to the time of day: onset of symptoms, consultation by the doctor, initial blood sampling, diagnosis and decrease of symptoms. Biochemical parameters at clinical presentation and consecutive changes within 24 h were recorded. RESULTS: In 65 pregnancies 77 HELLP episodes were well documented. Times of onset of symptoms and consultation by the doctor were significantly higher during the evening and night (p < 0.001), whereas times of diagnosis and decrease of symptoms occurred significantly more during the day (p < 0.001). In only 49.3% of the cases were diagnostic laboratory criteria met at clinical presentation. This was mainly due to platelet values in excess of 100 x 10(9)/l. Several hours later (median 8 h, range 2-23) the decrease in platelets occurred. CONCLUSIONS: A diurnal pattern exists in the clinical symptoms of HELLP syndrome that is characterized by an exacerbation during the night and recovery during the day. There is a considerable delay between the onset of symptoms and the fulfillment of diagnostic laboratory criteria. 相似文献
6.
7.
8.
9.
10.
Gerard J Molloy Derek W Johnston Chuan Gao Miles D Witham Joan M Gray Ishbel S Argo Allan D Struthers Marion E T McMurdo 《European journal of cardiovascular prevention and rehabilitation》2006,13(3):381-387
BACKGROUND: The impact of exercise programmes for heart failure on those close to the patient is largely unknown. We examined the effect of a hospital and home-based exercise intervention on burden, anxiety and depression of informal caregivers. DESIGN: The study was a randomized, controlled trial. Heart failure patients were randomized to a seated 12-week hospital-based exercise programme. Caregiver measures were gathered at baseline, 3 months later and 6 months following baseline. METHODS: Sixty caregivers (mean age 63.4 years, 65% female) of heart failure patients (n = 82, mean age 80.5 years, 44% female) participating in a trial of an exercise intervention were recruited. Caregiver burden, anxiety and depression were assessed. RESULTS: There were no differences in caregiver burden, depression or anxiety between the two groups of caregivers at baseline (caregiver burden, patient control 33.1 versus patient exercise 34.1; anxiety 4.1 versus 5.5; depression 2.8 versus 3.8). At 3 months there were no differences between caregivers in the two groups on outcomes. At 6-month follow-up caregivers of heart failure patients in the exercise group had burden scores that were significantly worse than the control group. There were no differences between the carers of exercise and control groups in anxiety and depression. Levels of anxiety and depression in the entire carer sample were marginally higher than reference values in a healthy non-clinical sample. CONCLUSION: The present exercise interventions for frail older patients did not benefit caregivers and was associated with an increase in caregiver burden. We suggest that future exercise interventions for heart failure patients should actively incorporate informal caregivers into research designs. 相似文献